Secondary cancers among children with acute lymphoblastic leukaemia treated by the Tokyo Children's Cancer Study Group protocols: a retrospective cohort study. (10th October 2013)

• Record Type: Journal Article
• Authors: Ishida, Yasushi; Maeda, Miho; Urayama, Kevin Y.; Kiyotani, Chikako; Aoki, Yuki; Kato, Yoko; Goto, Shoko; Sakaguchi, Sachi; Sugita, Kenichi; Tokuyama, Mika; Nakadate, Naoya; Ishii, Eizaburo; Tsuchida, Masahiro; Ohara, Akira
• Is Part Of: British journal of haematology. Volume 164:Number 1(2014:Jan.)
• Page Start: 101
• Page End: 112
• Publication Date: 2013-10-10
• Subjects: Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.12602
• Languages: English
• ISSNs: 0007-1048

Abstract

<abstract abstract-type="main" id="bjh12602-abs-0001"> <title>Summary</title> <p>With improvement in survival, it is important to evaluate the impact of treatment on secondary cancers in acute lymphoblastic leukaemia (ALL) survivors. A retrospective cohort study comprising 2918 children diagnosed with ALL and enrolled on Tokyo Children's Cancer Study Group (TCCSG) protocols between 1984 and 2005 was conducted to evaluate the incidence of secondary cancers and associated factors including treatment protocol, cranial irradiation and other characteristics of the primary ALL. Thirty‐seven patients developed secondary cancers, including acute myeloid leukaemia (<italic>n</italic> = 11), myelodysplastic syndrome (<italic>n</italic> = 5), non‐Hodgkin lymphoma (<italic>n</italic> = 2), brain tumours (<italic>n</italic> = 13) and other solid carcinomas (<italic>n</italic> = 6) within a median follow‐up duration of 9·5 years. The cumulative incidence of any secondary cancers was 1·0% (95% confidence interval (CI), 0·7–1·4%) at 10 years and 2·4% (95% CI, 1·5–3·7%) at 20 years, respectively. Standardized incidence rate ratio of secondary cancers was 9·3 (95% CI, 6·5–12·8). Multivariate analyses showed an increased risk of secondary cancers associated with the recent treatment protocol and cranial irradiation. There was no evidence of a reduction in secondary cancer incidence despite marked decreases in cranial irradiation use in the recent protocols.</p> </abstract>